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p53 status of head and neck cancer: relation to biologi'cal characteristics
and outcome of radiotherapy
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p53 status was investigated 99 patients with squamous cell carcinoma of the head and neck
region uniformly treated with accelekrated radiotherapy and whom tumour cell proliferation and DNA
aneuploidy were assessed using bromodeoxyuridine (BrdUrd) incorporation and flow cytometry (FCM).
Seventy-six percent of tumours were immunohistochemically positive for p53 protein, but heterogeneity was
noticed both in the percentage of cells positive for p53 and in their level of expression. However, tumours
which were either essentially all positive or all negative or showed sporadic positivity for p53 protein showed
no differences in their level of aneuploidy, proliferation rate, tissue organisation or outcome with radiotherapy.
There was a trend for those p53-positive tumours with the strongest expression to have more DNA aneuploidy
and deregulation of proliferation organisation than weaker expressors; but there were no differences in
proliferation rate or outcome of radiotherapy. These studies suggest that p53 protein stabihisation as assessed
by immnunohistochemistry does not have any major relationship with the biological characteristics and
outcome of squamous cell cancer treated by accelerated radiotherapy.
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Radiotherapy is an important component of modemn cancer
maaeet. Increased understanding of both tumour
biology and its relationship to response to radiotherapy
should have considerable therapeutic implications. The key
biological elements which play a role in deetermining the
outcome are proliferation, hypoxia, radiosensitivity and
DNA repair. These, in turn, are controlle by other factors,
both miicroenviironmiental and genetic. A leading role the
derangement of normal cell function has been attributed to
abnormalities in the p53 gene and its protein (Vogelstein and
Kunzler, 1992); it is currently the most commonly mutated
gene found in hulman cancer (Hollstein et al., 1991). Levels of
p53 protein in normal cells are usually low owing to a short
half-life. However, the protein becomes stabilised, and as a
consequence detectable, after exposure to DNA-damaging
agents such as UV light (Maltzman and Czyzyk, 1992; Lu
and Lane, 1993) and radiation (Kastan et al., 1992; Kuerbitz
et al., 1992). The elevated levels of p53 are associated with an
increase in the transcription of p53-responsive genes, result-
ing in the induction of growth arrest and apoptosis (Lane,
1994). The tumour-suppressor activity of p53 is probably a
result of this response. Loss of function by mutation and
protein stabilisation by induction in tumour cells results in
cells being able to survive and proliferate as the p53 GI
checkpoint will not function. This might result in not only
increased proliferation but also the accumulation of genetic
damage from which a subpopulation of more malignant cells
may emerge.
Clearly, this must have important implications for not only
the biological characteristics of the tumour population but
also its response to DNA-damaging agents such as radiation.
We chose to study a group of patients with head and neck
cancer who had been treated uniformly using the CHART
(continuous hyperfractionated accelerated radiotherapy)
regimen of radiotherapy (Saunders et al., 1991) and in whom
both proliferation and DNA aneuploidy had been assessed
using bromodeoxyuridmne incorporation and flow cytometry
(Wilson et al., 1991; Bennett et al., 1992).
Head and neck cancer represents an interesting model not
only for treatment by radiotherapy but also for tumorigenesis
and malignant progression. The development of neoplasms in
this site is referred to as field cancerisatiOn (Slaughter et a!.,
1953), in which an entire field of tissue is predisposed to the
development of cancer through repeated carcinogenic insult
to that field. This is manifest by a high occurrence of multi-
ple primary and secondary tumours (Cooper et a!., 1989).
Abnormalities in p53 are postulated to be an early event in
head and neck cancer development; Nees et al. (1993)
reported different mutations in tumour-distant epithelia from
patients with squamous carcinomas, while Shin et al. (1994)
demonstrated increasing incidence of p53 gene expression as
noirmal mucosa progressed through hyperplasia to dysplasia.
Siial, p53 mutation has been linked with further progres-
sion in that invasive lesions in the head and neck region have
a higher incidence of mutation than non-invasive lesions
(Boyle et a!., 1993). The aim of this study was to establish
the relationship between p53 and biological characteristics of
head and neck tumours and to determine whether p53 gene
expression had any infuence on outcome of curative
radiotherapy treatment.
Patients, materials and metbods
Patients
Since January 1985, patients presenting with locally advanced
squlamous cell carcinoma in the head and neck region have
been considered for treatment with the CHART regimen.
This study reports on a cohort of patients who received
CHART but were also suitable for study using bromode-
oxyuridine to measure cell kinetic profiles. Tumour samples
were obtained from 75 primary tumours and, in nine other
patients, from nodal disease. In a further 15 patients, the
biopsy was taken at a later time; nine patients had local
recurrence, two had nodal recurrence and four had distant
metastases outside the field of treatment. The distribution of
sites reflected the favouring of biopsy under local anaes-
thesia, and thus over 80% of the tumours studied were
tumours of the oral cavity, oropharynx or columella of the
nose.
Bromodeoxyuridine administration
A standard dose of 200 mg of bromodeoxyuridine (BrdUrd)
was administered to patients as a bolus injection in 20 ml of
0.9% saline; no adverse effects have been observed clinically.
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The material for injection was prepared as a freeze-dried
preparation from the CRC Drug Formulation Unit at Strath-
clyde University, Glasgow, UK.
Biopsy oftumour
Biopsies were taken before radiotherapy and most were per-
formed using an air-driven drill, although in some cases,
where appropriate, punch forceps or scalpel was used. For
the cell kinetc studies, the desired interval between DNA
precursor administration and biopsy was 6h; this ranged
from 4 to 8 h in 90% of cases, with the exact time interval
always being recorded. The material was examid macros-
copcally and comparable pieces fixed in 70% ethanol for
flow cytometry (FCM) and formol saline for immunohis-
tochemistry and for histopathology.
Flow cytometry
The details of the FCM methods have been described in
detail elsewhere (Wilson, 1991). Briefly, dual parameter stain-
ing of BrdUrd incorporation and DNA content, at a time
interval after injection, can yield information not only on
labelling index (LI) but also duration of S-phase (Ts) and
thus the potential doubling time (Tp). In addition, the DNA
index of the tumour can also be measured. Initially, FCM
analysis was carried out on an Ortho Systems 50-H
Cytofluorograf (Ortho Instruments, Westwood, MA USA)
and more recently on a FACScan (Becton Dickinson, San
Jose, CA, USA).
Immunohistochemistry
Histopathological examination was carried out using
haematoxylin and eosin to establish the tumour type, grading
and the proportions of tumour, normal tissue and debris in
the specimens. Two immunohistochemical analyses were also
performed on serial sections. These were BrdUrd incorpora-
tion and p53 protein expression.
BrdUrd localisation This has been described in detail
elsewhere (Bennett et al., 1992). In addition to determining
the LI of tumour cells identified by morphological criteria,
we have assessed the pattern of proliferation based on the
structural distribution of BrdUrd-labelled cells as a novel
indicator of tissue and prolferative deregulation. This com-
prises four classifications: marginal, in which proliferation is
restricted to basal and suprabasal layers; intermediate, in
which staining is mainly basal and suprabasal but is found in
deeper tissue layers; random, which shows a diffuse, disor-
ganised distribution; and mixed, which is a combination of
two or all three patterns (but usually involved random).
p53 staining and quantitation p53 was stained using D07
(Dako, High Wycombe, Bucks, UK) at a dilution of 1:50
overnight at 4 C in Tris-buffered saline (TBS) after five cycles
of 5 min microwave irradiations in 10 mM citrate buffer
(pH 6.0). Visualisation of p53 was achieved using a
biotinylated rabbit anti-mouse IgG (Dako) at a dilution of
1:300 for 1 h, followed by a 1:800 dilution of strep-
tavidin-peroxidase conjugate for a further hour. After
washing in TBS, the antibody complex was reacted with
diaminobenzidine for 10min and stained with Mayer's
haematoxylin after further washings.
p53 protein was assessed in two ways. Firstly, the pattern
of expression was assessed (Figure 1). This fell into three
basic categories; either the whole tumour specimen was essen-
tially positive for p53 (>80%) (Figure la) or negative
(<5%) (Figure lb), or there were specimens in which stain-
ing was sporadic (between 5% and 80%). The latter pattern
was sometimes related to differentiation (Figure Ic) in that
expression decreased as cells progressed towards maturation,
or it could be truly sporadic showing a random distribution
of positivity throughout the specimen (Figure Id). The other
striking feature of the staining was the variation in intensity.
This was semiquantitated as strong, moderate or weak in
those specimens showing positivity. This was controlled
between staining runs by visual assessment of a control speci-
men and by maintaining a standard procedure.
Follow-up study
All patients treated with CHART have been closely observed
in follow-up, with no patient being lost. The maximum
follow-up period for the live patients was 61 months and the
shortest 12 months; the median follow-up was 19 months.
Local or regional rcurr was nearly always confirmed by
histology. Correlations between parameters were performed
using regression analysis, and significance by Chi-
squared and log-rank and Wilcoxon tests.
Reist
p53 characteristics
Of the 99 tumours studied, 48 (49%) were essentially all
positive for p53 protein, 27 (27%) showed sporadic staining
and only 24 (24%) showed no evidence of p53 protein. The
numbers of patients in the subgroups were small, but it is
worthy of note that ofnine patients with nodal disease, seven
(78%) showed complete positivity, two (22%) showed
sporadic staining and none was negtive.
In the 75 p53-positive tumours, 31 (41%) were stained
intensely, 25 (33%) had moderate stai g intensity and 18
(24%) showed weak staining. No differences emerged
between primary and secondary tumours.
As might be expected, there was a strong correlation
between p53 staining intensity and staining pattem (Figure 2)
in that more intense staining was associated with tumours in
which all cells were positive for p53 and the inverse was true
for tumours which showed sporadic positivity.
p53 and DNA index
Figure 3 shows the incidence of aneuploidy as a function of
p53 staining pattern and intensity. The overall incidence of
aneuploidy was 49% in this group of tumours. The presence
or absence of p53 showed no relationship with gross DNA
abnormalities.
However, intensity ofstaining did show a relationship with
DNA index in that a significantly higher incidence of aneu-
ploidy (P<0.048) was found in tumours expressing high
amounts of p53 compared with those with weak expression.
Neither pattern of staining nor intensity showed any correla-
tion with absolute DNA index values.
p53 andproliferation
Table I summarises the relationship between p53 status and
cell kinetic characteristics. The overall conclusion was that
p53 showed no correlation with cell kinetic parameters. There
was a significant difference between median FCM Tpo
(P<0.047) and median FCM LI (P<0.012) when compar-
ing tumours showing moderate staining intensity with those
with strong expression. However, this significn was lost
when histologial data were used. This result can be at-
tributed to two factors: the higher incidence of aneuploidy
found in tumours with strong staining intensity and the fact
that FCM underesimates proliferation in diploid tumours
owing to its inability to discriminate normal from tumour
cells; histology overcomes this problem.
p53 and tumnow structure
Histological grading and pattern of proliferation can be used
as indicators of tissue deregulation. There were no major
differences in the distribution ofgrade among tumours which
either demonstrated different p53 staining patterns or stain-
ing intensities (Figure 4a).
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Figre 1 Staining patterns of p53 expression in squamous cancer of the head and neck. (a) A tumour in which all tumour cells are
positive with strong expression. (b) A tumour negative for p53. (c) Sporadic staining showing association with differentiation status.
(d) Sporadic staining with random positivity.
70 Proliferation pattern, which we consider to be a biological
indicator of tissue organisation in squamous cell carcinoma,
did show a trend towards the more disorganised tumours
(mixed and random) to be more commonly associated with
complete p53 positivity. Similarly, the same relationship was
found with intensity of staining, i.e. strong staining was more
commonly associated with more disorganised tumours
(Figure 4b). However, neither of these results was
significant.
p53 and local tumour control
Freedom from local recurrence represents a better indication
of radiation response than overall survival owing to other
confounding factors contributing to the latter; a significant
number of head and neck cancer patients may die of inter-
current heart disease. However, neither p53 pattern of stain-
ing (either individually or comparing all positive versus
negative tumours) (Figure 5a) nor p53 staining intensity
(Figure 5b) had any influence on the local tumour control of
squamous cell carcinoma of the head and neck region treated
by accelerated radiotherapy.
Micussios
The evolving picture of p53 gene function would suggest that
it plays an important role in cell cycle regulation by blocking
the entry into S-phase of cells that have sustained DNA
damage and, in some cases, triggering cell death by apoptosis
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Figue 2 Relationship between staining intensity and p53 posi-
tivity. The hatched bar represents tumours with sporadic p53
staining; the plain bar represents tumours in which all cells were
positive for p53.
(Lane, 1993). Disruption of this function by loss of cell cycle
control and gain in chromosomal rearrangement in the form
of gene amplification might be expected to correlate with
disease progression and response to DNA-damaging agents
such as radiation.
a
§i\\\\. IOur study agrees with others that p53 overexpression is a
frequent event in head and neck cancer. The overall detection
rate was 76% in this series from various sites within the head
and neck region, which is in agreement with a series of
papers recently reviewed on head and neck squamous cell
cancer (Field et al., 1993). These studies, like our own,
demonstrate a lack of correlation between p53 expression
and cinicopathological parameters.
Tumours clearly manifest different patterns of p53 expres-
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Figue 3 Relationship between DNA aneuploidy and p53 pat-
tern (left) or intensity of staining (right).
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sion; we attempted to semiquantitate two aspects of this
heterogeneity: the staining pattern and the intensity of stain-
ing. Only the latter parameter demonstrated any association
with clinical or biological characteristics. Strong expression
of p53 was more common in aneuploid tumours and in those
tumours which had lost their proliferation organisation.
Gapany et al. (1993) developed a scoring system for both
positivity and expression of p53 in histological material; their
study showed no correlation with grade or stage.
Lack of correlation between p53 overexpression and DNA
aneuploidy and proliferation was reported by Frank et al.
(1994) in hypopharyngeal tumours. In that study, prolifera-
tion was assessed as S-phase fraction from DNA profile
analysis. The technique we have used in this study gives a
more comprehensive measure of proliferation, but it has also
failed to show any association with p53 expression.
The participation of p53 protein in the cellular response to
DNA damage might suggest that alterations in protein ex-
pression would influence sensitivity to ionising radiation.
However, recent studies in cell lines have suggested that this
is not the case. Brachman et al. (1993) showed that p53
mutation did not correlate with radiosensitivity, assessed by
SF2 measurements, in a panel of 24 head and neck cancer
cell lines. Similarly, loss of the GI checkpoint in mammalian
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Fgue 5 p53 status and local tumour control after accelerated
radiotherapy. (a) staining pattern and (b) intensity of staining.
Table I Relationship between p53 and cell kinetic parameters
p53 staining pattern p53 staining intensity
Parameter All Sporadic Negative Weak Moderate Strong
FCM L1 8.1 6.9 7.4 7.3 5.0 9.2
FCM Ts 10.2 9.9 10.1 9.5 10.2 10.3
FCM Tpo> 3.9 4.4 4.8 4.3 6.1 3.2
Histology LI 13.7 14.9 15.9 16.4 12.6 15.0
Histology Tpo 2.5 2.5 3.2 2.4 2.6 2.4
The values quoted are medians. Histology LI is obtained from counting BrdUrd-labelled tumour
cells from stained sections. It was corrected to allow for cellular division between injection and
biopsy using a correction factor obtained from the FCM result (Bennett et al.. 1992). The histology
TP°J was calculated from the histology LI and FCM Ts.
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cells which were isogeneic, except for p53 functional status,
was not associated with increased sensitivity to ionising
radiation (Slichemnyer et al., 1993). This information,
coupled with earlier observations that caffeine-enhanced
radlotoxicity is primanrly a G, event and that delaying cell
cycle progression in AT cells does not enhance radiation
sensitivity, suggests that the GI checkpoint plays a minor role
in determining radiation sensitivity (Murnane and Schwartz,
1993). In this study, outcome ofaccelerated radiotherapy was
independent of the presence of p53 protein. If any schedule
might be expected to uncover a role for p53 in radiation
sensitivity it should be an accelerated schedule such as
CHART, which overcomes other confounding factors such as
proliferation.
The initial promise of p53 as a marker of disease progres-
sion and an indicator of DNA damage response is not yet
fulfilled in head and neck cancer, although this may not be
true of other cancers such as breast and colon. This is in
keeping with new knowledge of the function of this tumour-
suppressor gene. Compelling evidence now suggests that
switch-on of apoptosis may be the main function of altered
p53 levels in some cell types, e.g. haematopoietic,
thymocytes, whilst in others. e.g. fibroblasts. a cell cycle
delay is induced. The picture is also complicated by the
finding that stabilisation of p53 protein is not necessarily a
result of mutation-altered conformational changes (Lane,
1994). Protein stabilisation occurs in vivo after exposure to
mild sunburn (Hall et al., 1993). It is likely that stabilisation
might involve the action of other gene products, and
accumulation of p53 to high levels in tumour cells may be
more related to the tumour environment, and that the
tumour cell may be in a permanent state of damage related
to chromosomal breakages (Lane. 1994).
Future investigations for p53 in head and neck cancer
should establish its role in initiation and progression of the
disease, its interaction with mutagens, such as found in
tobacco, and viral proteins. Although this study showed no
correlation with outcome of accelerated radiotherapy, it
would be prudent to study p53 abnormalities with other
treatment regimens and with full knowledge of both protein
and gene status.
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